View Older Stories View More Recent Stories

May 27, 2016 10:27PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
May 27, 2016 09:38PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis
May 27, 2016 09:36PM Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
May 27, 2016 07:09AM CHMP Issues Positive Opinion on AbbVie's (ABBV) HUMIRA as non-Infectious Uveitis Treatment
May 27, 2016 07:00AM AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]
May 26, 2016 08:00AM AbbVie to Present at the Jefferies 2016 Healthcare Conference
May 24, 2016 11:00AM IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease
May 19, 2016 08:00AM AbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data
May 18, 2016 05:05PM AbbVie (ABBV) Announces Multiple Abstracts Evaluating Eight Medicines Across Cancer Types Presented at ASCO
May 18, 2016 05:00PM AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types
May 12, 2016 04:30PM AbbVie to Present at the UBS Global Health Care Conference
May 11, 2016 02:26PM Bristol-Myers Squibb (BMY), AbbVie (ABBV) Announce EC Approval of Empliciti Combo as Multiple Myeloma Treatment
May 11, 2016 02:25PM Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy
May 9, 2016 07:36AM AbbVie (ABBV) Announces FDA Update to IMBRUVICA Prescribing Info; Incldues Phase 3 Data for CLL
May 9, 2016 07:30AM U.S. FDA Expands IMBRUVICA® (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patie
Apr 29, 2016 09:19AM European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients
Apr 29, 2016 08:00AM AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference
Apr 29, 2016 07:39AM Biogen (BIIB), AbbVie (ABBV) Receive Positive CHMP Opinion on ZINBRYTA in MS
Apr 29, 2016 07:39AM Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Apr 28, 2016 07:21AM AbbVie (ABBV) to Acquire Stemcentrx in ~$5.8B Cash and Stock Deal
Apr 28, 2016 07:21AM AbbVie Reports First-Quarter 2016 Financial Results
Apr 28, 2016 07:20AM AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer
Apr 25, 2016 09:03AM AbbVie (ABBV) Receives FDA Approval of Viekira Pak sNDA for Use Without RBV
Apr 25, 2016 09:00AM AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic H
Apr 21, 2016 04:02PM CytomX (CTMX), AbbVie (ABBV) Enter Collaboration to Develop Probody Drug Conjugates Against CD71
Apr 21, 2016 04:01PM AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates
Apr 21, 2016 04:01PM CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates
Apr 21, 2016 06:28AM AbbVie (ABBV), argenx Enter Collaboration on ARGX-115 Against Novel Immuno-Oncology Target
Apr 21, 2016 01:07AM AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Apr 21, 2016 01:00AM argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Apr 20, 2016 08:35AM AbbVie (ABBV), University of Chicago Enter Cancer Research Collaboration
Apr 20, 2016 08:30AM AbbVie, University of Chicago collaborate to advance cancer research
Apr 20, 2016 08:13AM Biogen (BIIB), AbbVie (ABBV) Present Data at AAN Highlighting Impact of ZINBRYTA on Cognitive Outcomes and Targeted MOA
Apr 20, 2016 07:30AM Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action
Apr 20, 2016 07:00AM AbbVie to Present at the Deutsche Bank 41st Annual Health Care Conference
Apr 18, 2016 06:46AM AbbVie (ABBV) Announces Positive Data from ABT-493, ABT-530 Phase 2 in HCV Genotypes 1 - 6 (ENTA)
Apr 16, 2016 01:00AM AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6
Apr 15, 2016 06:38AM AbbVie (ABBV) Issues Positive Update on ABT-493 and ABT-530 w/ RBV in HCV GT1 (ENTA)
Apr 15, 2016 01:00AM AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
Apr 15, 2016 01:00AM AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry
Apr 14, 2016 01:00AM AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatm
Apr 12, 2016 01:07AM AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion
Apr 11, 2016 04:32PM AbbVie (ABBV) Announces Receipt of Accelerated FDA Approval for Venclexta in CLL
Apr 11, 2016 04:31PM AbbVie Receives FDA Accelerated Approval of Venclexta™ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion
Apr 7, 2016 08:00AM AbbVie to Host First-Quarter Earnings Conference Call
Apr 4, 2016 07:08AM AbbVie (ABBV) Affirms Receipt of Positive EMA CHMP Opinion for HUMIRA in Crohn's Disease
Apr 4, 2016 07:00AM AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Mar 30, 2016 07:00AM AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 201
Mar 8, 2016 04:15PM AbbVie to Present at Barclays Global Healthcare Conference
Mar 7, 2016 08:02AM AbbVie (ABBV), Boehringer Ingelheim Enter Agreement for BI 655066 Development, Commercialization
View More Recent Stories View Older Stories